AEMD Nasdaq Earnings call
Aethlon Medical Inc. (AEMD) · Q4 2026 results
Share price: $5.53 · 2026-11-11
Results Q4 2026 vs Q1 2026 · previous quarter · published 10 Jun 2026 and 13 Aug 2025
Management sounded cautious, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
—
No financial figures for this pair
2 · How management spoke
Cautious
Among the least upbeat of all company calls
Answers to analysts: cautious, in line with the script.
Similar to last call.
3 · What stood out
Figure
AEMD's consolidated operating expenses fell 21.9% year-over-year to about $7.3 million.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$5.53
close of 2026-11-11
P/E
0.2
today
Revenue growth, 3 years
−100.0% a year
compound annual rate (CAGR)
Free cash flow 2024
−$0.0B
Free cash flow 2025
−$0.0B
Free cash flow 2026
−$0.0B
Read between the lines
-
Key theme
AEMD completed enrollment and treatment for cohort 2 of its Australian oncology trial across three participants, moving the cancer study forward.
Source quote
“Enrollment and treatment of participants in cohort 2 of our Australian oncology trial have been completed. As a reminder, 3 participants in Cohort 2 received 2 4-hour hemopreia fire treatments during a 1-week treatment period.”
-
Key theme
AEMD completed its first healthy plasma test using one large volume sample for platelet EV removal implicated in disease, pointing to a new revenue driver.
Source quote
“What we did is the first instance is test healthy plasma to look for platelet removal of EVs, platelet drive... -- is implicated in the disease. And we did that in a single large volume healthy plasma sample.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q4 2026. Ring: Q1 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“Taken together, these achievements demonstrate continued execution against our key priorities of clinical development, platform expansion, intellectual property growth and disciplined resource management.”
Topics
Most discussed now
- New Formal statistical analyses comparing the effects of the 3 different Hemopurifier dosing regimens on these parameters will be performed…
- New As a reminder, this is a 9 to 18 patient study designed to evaluate the safety and the feasibility of...
- New Aethlon Medical is purchasing large volume rheumatoid arthritis samples.
- New Secondary endpoint is surrogate markers looking at the Hemopurifiers activity, and those would be EV removal, extracellular vesicle removal…
- Aethlon Medical is advancing its preclinical extracellular vesicle research activities, including studies...
Faded since Q1 2026
- Dropped With Aethlon Medical will now cover the business update portion of this call.
- Dropped Aethlon Medical also saw a meaningful reduction in legal fees after transitioning to a new firm and lower scientific consulting costs...
- Dropped One advantage of India was that all of the previous viral trials Aethlon Medical did.
- Dropped Aethlon Medical is actively recruiting plans for 2 additional sites, again, to augment enrollment.
Latest announcements
Official filings, newest first.
- Director or officer change; Shareholder vote results · SEC 8-K
- Material agreement; 5.01; Regulation FD disclosure · SEC 8-K
- Director or officer change · SEC 8-K
- Other events · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K
- Change to shareholder rights; Articles or bylaws amended · SEC 8-K
- Material agreement; Other events · SEC 8-K
- Results of operations; Regulation FD disclosure · SEC 8-K